

Atanasio Pandiella

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4648007/publications.pdf>

Version: 2024-02-01

222
papers

10,951
citations

29994

54
h-index

40881

93
g-index

225
all docs

225
docs citations

225
times ranked

14247
citing authors

#	ARTICLE	IF	CITATIONS
1	Membrane-Anchored Growth Factors. Annual Review of Biochemistry, 1993, 62, 515-541.	5.0	641
2	Sox2 expression in breast tumours and activation in breast cancer stem cells. Oncogene, 2012, 31, 1354-1365.	2.6	447
3	Antitumor Effects of Doxorubicin in Combination With Anti-epidermal Growth Factor Receptor Monoclonal Antibodies. Journal of the National Cancer Institute, 1993, 85, 1327-1333.	3.0	372
4	Neutrophils in cancer: prognostic role and therapeutic strategies. Molecular Cancer, 2017, 16, 137.	7.9	295
5	Extracellular Signal-regulated Kinase Phosphorylates Tumor Necrosis Factor α -converting Enzyme at Threonine 735: A Potential Role in Regulated Shedding. Molecular Biology of the Cell, 2002, 13, 2031-2044.	0.9	273
6	Inhibition of Src Family Kinases and Receptor Tyrosine Kinases by Dasatinib: Possible Combinations in Solid Tumors. Clinical Cancer Research, 2011, 17, 5546-5552.	3.2	247
7	The Histone Deacetylase Inhibitor LBH589 Is a Potent Antimyeloma Agent that Overcomes Drug Resistance. Cancer Research, 2006, 66, 5781-5789.	0.4	233
8	Cleavage of the membrane precursor for transforming growth factor alpha is a regulated process.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 1726-1730.	3.3	219
9	Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood, 2006, 107, 3575-3583.	0.6	188
10	HER3 Overexpression and Survival in Solid Tumors: A Meta-analysis. Journal of the National Cancer Institute, 2013, 105, 266-273.	3.0	168
11	Erk5 Participates in Neuregulin Signal Transduction and Is Constitutively Active in Breast Cancer Cells Overexpressing ErbB2. Molecular and Cellular Biology, 2002, 22, 270-285.	1.1	163
12	Transforming Growth Factor β Engages TACE and ErbB3 To Activate Phosphatidylinositol-3 Kinase/Akt in ErbB2-Overexpressing Breast Cancer and Desensitizes Cells to Trastuzumab. Molecular and Cellular Biology, 2008, 28, 5605-5620.	1.1	153
13	Differential Shedding of Transmembrane Neuregulin Isoforms by the Tumor Necrosis Factor- α -Converting Enzyme. Molecular and Cellular Neurosciences, 2000, 16, 631-648.	1.0	152
14	Preclinical development of molecular-targeted agents for cancer. Nature Reviews Clinical Oncology, 2011, 8, 200-209.	12.5	145
15	In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica, 2010, 95, 794-803.	1.7	144
16	Activation of the PI3K/mTOR/AKT Pathway and Survival in Solid Tumors: Systematic Review and Meta-Analysis. PLoS ONE, 2014, 9, e95219.	1.1	140
17	The cytoplasmic carboxy-terminal amino acid specifies cleavage of membrane TGF β into soluble growth factor. Cell, 1992, 71, 1157-1165.	13.5	136
18	Resistance to Antibody-Drug Conjugates. Cancer Research, 2018, 78, 2159-2165.	0.4	136

#	ARTICLE	IF	CITATIONS
19	Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors. <i>Leukemia</i> , 2009, 23, 1515-1527.	3.3	122
20	New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. <i>Lancet Oncology</i> , 2008, 9, 1157-1165.	5.1	116
21	The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. <i>Leukemia</i> , 2013, 27, 430-440.	3.3	112
22	Genetic Abnormalities and Patterns of Antigenic Expression in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2005, 11, 3661-3667.	3.2	109
23	TrkA receptor ectodomain cleavage generates a tyrosine-phosphorylated cell-associated fragment.. <i>Journal of Cell Biology</i> , 1996, 132, 427-436.	2.3	104
24	Resistance to the Antibody-Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic Activity. <i>Cancer Research</i> , 2017, 77, 4639-4651.	0.4	103
25	Expression of Erk5 in Early Stage Breast Cancer and Association with Disease Free Survival Identifies this Kinase as a Potential Therapeutic Target. <i>PLoS ONE</i> , 2009, 4, e5565.	1.1	99
26	Aplidin, a Marine Organism-Derived Compound with Potent Antimyeloma Activity <i>In vitro</i> and <i>In vivo</i> . <i>Cancer Research</i> , 2008, 68, 5216-5225.	0.4	98
27	Neuregulins and Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 3237-3241.	3.2	95
28	P-Rex1 participates in Neuregulin-ErbB signal transduction and its expression correlates with patient outcome in breast cancer. <i>Oncogene</i> , 2011, 30, 1059-1071.	2.6	92
29	EGF raises cytosolic Ca ²⁺ in A431 and Swiss 3T3 cells by a dual mechanism. <i>Experimental Cell Research</i> , 1987, 170, 175-185.	1.2	89
30	Early rise of cytosolic Ca ²⁺ -induced by NGF in PC12 and chromaffin cells. <i>FEBS Letters</i> , 1986, 208, 48-51.	1.3	88
31	Cellular Plasticity Confers Migratory and Invasive Advantages to a Population of Glioblastoma-Initiating Cells that Infiltrate Peritumoral Tissue. <i>Stem Cells</i> , 2013, 31, 1075-1085.	1.4	83
32	Multifunctional role of Erk5 in multiple myeloma. <i>Blood</i> , 2005, 105, 4492-4499.	0.6	82
33	ω-Conotoxin binding and effects on calcium channel function in human neuroblastoma and rat pheochromocytoma cell lines. <i>FEBS Letters</i> , 1988, 235, 178-182.	1.3	78
34	Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks. <i>Blood</i> , 2009, 113, 3781-3791.	0.6	78
35	Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer. <i>Oncogene</i> , 2014, 33, 148-156.	2.6	78
36	TGF-β1 induces COX-2 expression and PGE2 synthesis through MAPK and PI3K pathways in human mesangial cells. <i>Kidney International</i> , 2006, 70, 901-909.	2.6	75

#	ARTICLE	IF	CITATIONS
37	Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients. <i>Leukemia</i> , 2012, 26, 1862-1869.	3.3	73
38	In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone. <i>Leukemia</i> , 2015, 29, 705-714.	3.3	72
39	Autocrine Regulation of Membrane Transforming Growth Factor- β Cleavage. <i>Journal of Biological Chemistry</i> , 1996, 271, 3279-3284.	1.6	69
40	Endoglin Modulation of TGF- β 1-Induced Collagen Synthesis is Dependent on ERK1/2 MAPK Activation. <i>Cellular Physiology and Biochemistry</i> , 2006, 18, 135-142.	1.1	65
41	Oncogenic Targets, Magnitude of Benefit, and Market Pricing of Antineoplastic Drugs. <i>Journal of Clinical Oncology</i> , 2011, 29, 2543-2549.	0.8	64
42	Activation of ErbB2 by Overexpression or by Transmembrane Neuregulin Results in Differential Signaling and Sensitivity to Herceptin. <i>Cancer Research</i> , 2005, 65, 6801-6810.	0.4	63
43	Activated release of membrane-anchored TGF-alpha in the absence of cytosol. <i>Journal of Cell Biology</i> , 1993, 122, 95-101.	2.3	62
44	ERK5 Activates NF- κ B in Leukemic T Cells and Is Essential for Their Growth In Vivo. <i>Journal of Immunology</i> , 2006, 177, 7607-7617.	0.4	62
45	Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 383.	3.5	62
46	An Overview of Antibody Conjugated Polymeric Nanoparticles for Breast Cancer Therapy. <i>Pharmaceutics</i> , 2020, 12, 802.	2.0	62
47	Dasatinib as a Bone-Modifying Agent: Anabolic and Anti-Resorptive Effects. <i>PLoS ONE</i> , 2012, 7, e34914.	1.1	61
48	Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 7006-7019.	3.2	61
49	Stimulation of cleavage of membrane proteins by calmodulin inhibitors. <i>Biochemical Journal</i> , 2000, 346, 359-367.	1.7	59
50	Transforming growth factor- β 1 induces collagen synthesis and accumulation via p38 mitogen-activated protein kinase (MAPK) pathway in cultured L6E9myoblasts. <i>FEBS Letters</i> , 2002, 513, 282-288.	1.3	59
51	Bortezomib is an efficient agent in plasma cell leukemias. <i>International Journal of Cancer</i> , 2005, 114, 665-667.	2.3	59
52	Role of metalloproteinases MMP-9 and MT1-MMP in CXCL12-promoted myeloma cell invasion across basement membranes. <i>Journal of Pathology</i> , 2006, 208, 108-118.	2.1	59
53	The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair. <i>Leukemia</i> , 2009, 23, 2265-2274.	3.3	58
54	The mitogen-activated protein kinase ERK5 regulates the development and growth of hepatocellular carcinoma. <i>Gut</i> , 2015, 64, 1454-1465.	6.1	58

#	ARTICLE	IF	CITATIONS
55	Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond. <i>Trends in Cancer</i> , 2020, 6, 130-146.	3.8	58
56	Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells. <i>Annals of Oncology</i> , 2008, 19, 1860-1869.	0.6	57
57	The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype. <i>Haematologica</i> , 2008, 93, 57-66.	1.7	56
58	Colorectal cancer and medicinal plants: Principle findings from recent studies. <i>Biomedicine and Pharmacotherapy</i> , 2018, 107, 408-423.	2.5	56
59	Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents. <i>British Journal of Haematology</i> , 2003, 123, 858-868.	1.2	53
60	Neuregulin Expression Modulates Clinical Response to Trastuzumab in Patients With Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 2656-2663.	0.8	53
61	ERK5/BMK1 Is a Novel Target of the Tumor Suppressor VHL: Implication in Clear Cell Renal Carcinoma. <i>Neoplasia</i> , 2013, 15, 649-657.	2.3	53
62	Ubiquitin-conjugating enzyme E2T (UBE2T) and denticleless protein homolog (DTL) are linked to poor outcome in breast and lung cancers. <i>Scientific Reports</i> , 2017, 7, 17530.	1.6	53
63	HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates. <i>Breast Cancer Research</i> , 2020, 22, 15.	2.2	53
64	A new simple whole blood flow cytometry-based method for simultaneous identification of activated cells and quantitative evaluation of cytokines released during activation. <i>Laboratory Investigation</i> , 2004, 84, 1387-1398.	1.7	52
65	Personalized therapies in the cancer "omics" era. <i>Molecular Cancer</i> , 2010, 9, 202.	7.9	52
66	Mitogen-activated protein kinase-dependent and -independent routes control shedding of transmembrane growth factors through multiple secretases. <i>Biochemical Journal</i> , 2002, 363, 211-221.	1.7	51
67	Targeting the EGF/HER Ligand-Receptor System in Cancer. <i>Current Pharmaceutical Design</i> , 2016, 22, 5887-5898.	0.9	51
68	Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands. <i>International Journal of Oncology</i> , 2012, 41, 1128-1138.	1.4	50
69	Cleavage of the TrkA neurotrophin receptor by multiple metalloproteases generates signalling-competent truncated forms. <i>European Journal of Neuroscience</i> , 1999, 11, 1421-1430.	1.2	49
70	Induction of B-Chronic Lymphocytic Leukemia Cell Apoptosis by Arsenic Trioxide Involves Suppression of the Phosphoinositide 3-Kinase/Akt Survival Pathway via c-jun-NH2 Terminal Kinase Activation and PTEN Upregulation. <i>Clinical Cancer Research</i> , 2010, 16, 4382-4391.	3.2	49
71	Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling. <i>BMC Cancer</i> , 2014, 14, 302.	1.1	49
72	PDGF-induced receptor phosphorylation and phosphoinositide hydrolysis are unaffected by protein kinase C activation in mouse Swiss 3T3 and human skin fibroblasts. <i>Biochemical and Biophysical Research Communications</i> , 1986, 137, 343-350.	1.0	48

#	ARTICLE	IF	CITATIONS
73	ODZ1 allows glioblastoma to sustain invasiveness through a Myc-dependent transcriptional upregulation of RhoA. <i>Oncogene</i> , 2017, 36, 1733-1744.	2.6	48
74	Predominance of mTORC1 over mTORC2 in the Regulation of Proliferation of Ovarian Cancer Cells: Therapeutic Implications. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1342-1352.	1.9	47
75	Endoglin Expression Regulates Basal and TGF- β 1-induced Extracellular Matrix Synthesis in Cultured L ₆ E ₉ Myoblasts. <i>Cellular Physiology and Biochemistry</i> , 2004, 14, 301-310.	1.1	46
76	Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies. <i>Oncotarget</i> , 2017, 8, 22218-22234.	0.8	46
77	Potent Antimyeloma Activity of a Novel ERK5/CDK Inhibitor. <i>Clinical Cancer Research</i> , 2013, 19, 2677-2687.	3.2	45
78	Impaired Trafficking and Activation of Tumor Necrosis Factor- α -converting Enzyme in Cell Mutants Defective in Protein Ectodomain Shedding. <i>Journal of Biological Chemistry</i> , 2003, 278, 25933-25939.	1.6	44
79	Multisite phosphorylation of Erk5 in mitosis. <i>Journal of Cell Science</i> , 2010, 123, 3146-3156.	1.2	44
80	Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2552-2562.	1.9	44
81	Mitogen-activated protein kinase-dependent and -independent routes control shedding of transmembrane growth factors through multiple secretases. <i>Biochemical Journal</i> , 2002, 363, 211.	1.7	43
82	Effect of Multikinase Inhibitors on Caspase-Independent Cell Death and DNA Damage in HER2-Overexpressing Breast Cancer Cells. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1432-1446.	3.0	43
83	Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease. <i>Oncotarget</i> , 2014, 5, 8284-8305.	0.8	43
84	Identifying Breast Cancer Druggable Oncogenic Alterations: Lessons Learned and Future Targeted Options. <i>Clinical Cancer Research</i> , 2008, 14, 961-970.	3.2	42
85	Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: Therapeutic implications. <i>International Journal of Cancer</i> , 2012, 131, 244-252.	2.3	42
86	NADPH Oxidases as Therapeutic Targets in Chronic Myelogenous Leukemia. <i>Clinical Cancer Research</i> , 2014, 20, 4014-4025.	3.2	42
87	ERK2, but Not ERK1, Mediates Acquired and <i>de novo</i> Resistance to Imatinib Mesylate: Implication for CML Therapy. <i>PLoS ONE</i> , 2009, 4, e6124.	1.1	41
88	Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer. <i>Annals of Oncology</i> , 2007, 18, 421-430.	0.6	40
89	Breast Cancer Heterogeneity and Response to Novel Therapeutics. <i>Cancers</i> , 2020, 12, 3271.	1.7	40
90	Therapeutic potential of ERK5 targeting in triple negative breast cancer. <i>Oncotarget</i> , 2014, 5, 11308-11318.	0.8	40

#	ARTICLE	IF	CITATIONS
91	Targeting HER Receptors in Cancer. <i>Current Pharmaceutical Design</i> , 2013, 19, 808-817.	0.9	39
92	Mechanism of apoptosis induced by IFN- γ in human myeloma cells: Role of Jak1 and Bim and potentiation by rapamycin. <i>Cellular Signalling</i> , 2007, 19, 844-854.	1.7	38
93	Prognostic Value of Lymphocyte-Activation Gene 3 (LAG3) in Cancer: A Meta-Analysis. <i>Frontiers in Oncology</i> , 2019, 9, 1040.	1.3	38
94	Effect of p95HER2/611CTF on the Response to Trastuzumab and Chemotherapy. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	36
95	Proteolysis targeting chimeras (PROTACs) in cancer therapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 189.	3.5	36
96	Plasma membrane hyperpolarization and [Ca ²⁺] _i increase induced by fibroblast growth factor in NIH-3T3 fibroblasts: Resemblance to early signals generated by platelet-derived growth factor. <i>Biochemical and Biophysical Research Communications</i> , 1989, 163, 1325-1331.	1.0	35
97	Erk5 is activated and acts as a survival factor in mitosis. <i>Cellular Signalling</i> , 2007, 19, 1964-1972.	1.7	35
98	The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells. <i>British Journal of Haematology</i> , 2008, 141, 470-482.	1.2	35
99	CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype. <i>Haematologica</i> , 2012, 97, 1110-1114.	1.7	34
100	\hat{I}^2 -Lapachone analogs with enhanced antiproliferative activity. <i>European Journal of Medicinal Chemistry</i> , 2012, 53, 264-274.	2.6	34
101	Prognostic relevance of receptor tyrosine kinase expression in breast cancer: A meta-analysis. <i>Cancer Treatment Reviews</i> , 2014, 40, 1048-1055.	3.4	34
102	Expression of MHC class I, HLA-A and HLA-B identifies immune-activated breast tumors with favorable outcome. <i>Oncolimmunology</i> , 2019, 8, e1629780.	2.1	34
103	Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 693-701.	1.1	34
104	Deficient Spindle Assembly Checkpoint in Multiple Myeloma. <i>PLoS ONE</i> , 2011, 6, e27583.	1.1	33
105	Overexpression of HER2 signaling to WAVE2- α Arp2/3 complex activates MMP-independent migration in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 126, 311-318.	1.1	33
106	BET inhibitors as novel therapeutic agents in breast cancer. <i>Oncotarget</i> , 2017, 8, 71285-71291.	0.8	33
107	Tumor-Infiltrating Lymphocytes in Breast Cancer: Ready for Prime Time?. <i>Journal of Clinical Oncology</i> , 2015, 33, 1298-1299.	0.8	32
108	Trastuzumab and Antiestrogen Therapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2006, 29, 90-95.	0.6	31

#	ARTICLE	IF	CITATIONS
109	Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity. <i>Haematologica</i> , 2008, 93, 851-859.	1.7	31
110	Interaction between Hormonal Receptor Status, Age and Survival in Patients with BRCA1/2 Germline Mutations: A Systematic Review and Meta-Regression. <i>PLoS ONE</i> , 2016, 11, e0154789.	1.1	31
111	A new method for detecting TNF- α -secreting cells using direct-immunofluorescence surface membrane stainings. <i>Journal of Immunological Methods</i> , 2002, 264, 77-87.	0.6	30
112	Circulating DNA and Survival in Solid Tumors. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 399-406.	1.1	30
113	HER3 targeting with an antibody-drug conjugate bypasses resistance to anti-HER2 therapies. <i>EMBO Molecular Medicine</i> , 2020, 12, e11498.	3.3	30
114	Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs. <i>Cancers</i> , 2022, 14, 154.	1.7	30
115	Erk5 nuclear location is independent on dual phosphorylation, and favours resistance to TRAIL-induced apoptosis. <i>Cellular Signalling</i> , 2007, 19, 1473-1487.	1.7	29
116	Transcriptomic immunologic signature associated with favorable clinical outcome in basal-like breast tumors. <i>PLoS ONE</i> , 2017, 12, e0175128.	1.1	28
117	Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses. <i>Oncotarget</i> , 2015, 6, 39538-39549.	0.8	27
118	Pemetrexed acts as an antimyeloma agent by provoking cell cycle blockade and apoptosis. <i>Leukemia</i> , 2007, 21, 797-804.	3.3	26
119	Intracellular Calcium Homeostasis in a Human Neuroblastoma Cell Line: Modulation by Depolarization, Cholinergic Receptors, and γ -Latrotoxin. <i>Journal of Neurochemistry</i> , 1988, 50, 1708-1713.	2.1	25
120	Oleic Acid Blocks Epidermal Growth Factor-Activated Early Intracellular Signals without Altering the Ensuing Mitogenic Response. <i>Experimental Cell Research</i> , 1993, 205, 365-373.	1.2	24
121	Signalling-competent truncated forms of ErbB2 in breast cancer cells: differential regulation by protein kinase C and phosphatidylinositol 3-kinase. <i>Biochemical Journal</i> , 1999, 344, 339-348.	1.7	24
122	Molecular Pathways: P-Rex in Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 4564-4569.	3.2	24
123	A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study. <i>Oncotarget</i> , 2017, 8, 73144-73153.	0.8	24
124	A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors. <i>Frontiers in Immunology</i> , 2019, 10, 2802.	2.2	24
125	Antitumor activity of the novel multi-kinase inhibitor EC-70124 in triple negative breast cancer. <i>Oncotarget</i> , 2015, 6, 27923-27937.	0.8	24
126	Protein kinase C-mediated feed back inhibition of the Ca ²⁺ response at the EGF receptor. <i>Biochemical and Biophysical Research Communications</i> , 1987, 149, 145-151.	1.0	23

#	ARTICLE	IF	CITATIONS
127	The Extracellular Linker of pro-Neuregulin-1 α 2c Is Required for Efficient Sorting and Juxtacrine Function. <i>Molecular Biology of the Cell</i> , 2007, 18, 380-393.	0.9	23
128	The mitogen-activated protein kinase Erk5 mediates human mesangial cell activation. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 3403-3411.	0.4	23
129	<i>In Silico</i> Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer Treatment. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1823-1833.	1.9	23
130	Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors. <i>Oncotarget</i> , 2017, 8, 19478-19490.	0.8	23
131	1-Adrenergic Stimulation of <i>in Vitro</i> Growth Hormone Release and Cytosolic Free Ca ²⁺ in Rat Somatotrophs*. <i>Endocrinology</i> , 1988, 122, 1419-1425.	1.4	22
132	Autophagy inhibition sensitizes multiple myeloma cells to 17-dimethylaminoethylamino-17-demethoxygeldanamycin-induced apoptosis. <i>Leukemia Research</i> , 2010, 34, 1533-1538.	0.4	22
133	Genomic Mapping Identifies Mutations in RYR2 and AHNAK as Associated with Favorable Outcome in Basal-Like Breast Tumors Expressing PD1/PD-L1. <i>Cancers</i> , 2020, 12, 2243.	1.7	22
134	<i>In silico</i> analyses identify gene-sets, associated with clinical outcome in ovarian cancer: role of mitotic kinases. <i>Oncotarget</i> , 2016, 7, 22865-22872.	0.8	21
135	Neuregulin expression in solid tumors: Prognostic value and predictive role to anti-HER3 therapies. <i>Oncotarget</i> , 2016, 7, 45042-45051.	0.8	21
136	Enhancement of antiproliferative activity by molecular simplification of catalpol. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 2515-2523.	1.4	20
137	The evolving landscape of protein kinases in breast cancer: Clinical implications. <i>Cancer Treatment Reviews</i> , 2013, 39, 68-76.	3.4	20
138	Genomic Signatures of Immune Activation Predict Outcome in Advanced Stages of Ovarian Cancer and Basal-Like Breast Tumors. <i>Frontiers in Oncology</i> , 2019, 9, 1486.	1.3	20
139	Stimulation of cleavage of membrane proteins by calmodulin inhibitors. <i>Biochemical Journal</i> , 2000, 346, 359.	1.7	19
140	N-terminal cleavage of proTGF β 1 occurs at the cell surface by a TACE-independent activity. <i>Biochemical Journal</i> , 2005, 389, 161-172.	1.7	19
141	Mitotic Arrest Induced by a Novel Family of DNA Topoisomerase II Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 3835-3839.	2.9	18
142	Effect of Oncoxin Oral Solution in HER2-Overexpressing Breast Cancer. <i>Nutrition and Cancer</i> , 2015, 67, 1159-1169.	0.9	18
143	Breast cancer dissemination promoted by a neuregulin-collagenase 3 signalling node. <i>Oncogene</i> , 2016, 35, 2756-2765.	2.6	18
144	Mitotic read-out genes confer poor outcome in luminal A breast cancer tumors. <i>Oncotarget</i> , 2017, 8, 21733-21740.	0.8	18

#	ARTICLE	IF	CITATIONS
145	Novel Tyrosine Kinase Inhibitors in the Treatment of Cancer. <i>Current Drug Targets</i> , 2009, 10, 575-576.	1.0	18
146	The Activation of the Sox2 RR2 Pluripotency Transcriptional Reporter in Human Breast Cancer Cell Lines is Dynamic and Labels Cells with Higher Tumorigenic Potential. <i>Frontiers in Oncology</i> , 2014, 4, 308.	1.3	17
147	Antitumoral effect of Ocoxin on acute myeloid leukemia. <i>Oncotarget</i> , 2016, 7, 6231-6242.	0.8	17
148	Refining Early Antitumoral Drug Development. <i>Trends in Pharmacological Sciences</i> , 2018, 39, 922-925.	4.0	17
149	Antitumoral activity of the mithralog EC-8042 in triple negative breast cancer linked to cell cycle arrest in G2. <i>Oncotarget</i> , 2015, 6, 32856-32867.	0.8	17
150	ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor. <i>International Journal of Cancer</i> , 2013, 133, 235-246.	2.3	16
151	Phosphorylation of P-Rex1 at serine 1169 participates in IGF-1R signaling in breast cancer cells. <i>Cellular Signalling</i> , 2013, 25, 2281-2289.	1.7	16
152	Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors. <i>PLoS ONE</i> , 2019, 14, e0209134.	1.1	16
153	In silico transcriptomic mapping of integrins and immune activation in Basal-like and HER2+ breast cancer. <i>Cellular Oncology (Dordrecht)</i> , 2021, 44, 569-580.	2.1	16
154	Clinical, genetic and pharmacological data support targeting the MEK5/ERK5 module in lung cancer. <i>Npj Precision Oncology</i> , 2021, 5, 78.	2.3	16
155	Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling. <i>Oncotarget</i> , 2015, 6, 30057-30071.	0.8	15
156	Functional transcriptomic annotation and protein-protein interaction analysis identify EZH2 and UBE2C as key upregulated proteins in ovarian cancer. <i>Cancer Medicine</i> , 2018, 7, 1896-1907.	1.3	14
157	Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: understanding clinical trial results. <i>Oncotarget</i> , 2018, 9, 31915-31919.	0.8	14
158	Prognostic value of receptor tyrosine kinase-like orphan receptor (ROR) family in cancer: A meta-analysis. <i>Cancer Treatment Reviews</i> , 2019, 77, 11-19.	3.4	14
159	Antimyeloma Efficacy of Plitidepsin (Aplidin®): From Bench to the Bedside.. <i>Blood</i> , 2007, 110, 1178-1178.	0.6	14
160	Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response. <i>Haematologica</i> , 2011, 96, 687-695.	1.7	13
161	Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer. <i>Cancer Letters</i> , 2020, 491, 50-59.	3.2	13
162	DNA-damage related genes and clinical outcome in hormone receptor positive breast cancer. <i>Oncotarget</i> , 2017, 8, 62834-62841.	0.8	13

#	ARTICLE	IF	CITATIONS
163	Do We Have to Change the Way Targeted Drugs Are Developed?. <i>Journal of Clinical Oncology</i> , 2010, 28, e420-e421.	0.8	12
164	Paclitaxel-Trastuzumab Mixed Nanovehicle to Target HER2-Overexpressing Tumors. <i>Nanomaterials</i> , 2019, 9, 948.	1.9	12
165	TRAIL receptor activation overcomes resistance to trastuzumab in HER2 positive breast cancer cells. <i>Cancer Letters</i> , 2019, 453, 34-44.	3.2	12
166	Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple-negative breast cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 3117-3127.	1.6	12
167	Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5096-5108.	3.2	12
168	Transforming growth factor- β . <i>Biochemical Society Transactions</i> , 1991, 19, 259-262.	1.6	11
169	RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications. <i>Investigational New Drugs</i> , 2013, 31, 200-205.	1.2	11
170	Antiproliferative Effect of <i>Synadenium grantii</i> Hook f. stems (Euphorbiaceae) and a Rare Phorbol Diterpene Ester. <i>International Journal of Toxicology</i> , 2016, 35, 666-671.	0.6	11
171	Antitumoral effect of Ocoxin in hepatocellular carcinoma. <i>Oncology Letters</i> , 2017, 14, 1950-1958.	0.8	11
172	Evaluation of transcriptionally regulated genes identifies NCOR1 in hormone receptor negative breast tumors and lung adenocarcinomas as a potential tumor suppressor gene. <i>PLoS ONE</i> , 2018, 13, e0207776.	1.1	11
173	Transcriptome evolution from breast epithelial cells to basal-like tumors. <i>Oncotarget</i> , 2018, 9, 453-463.	0.8	11
174	Mapping Bromodomains in breast cancer and association with clinical outcome. <i>Scientific Reports</i> , 2019, 9, 5734.	1.6	11
175	Adaptive resistance to trastuzumab impairs response to neratinib and lapatinib through deregulation of cell death mechanisms. <i>Cancer Letters</i> , 2020, 470, 161-169.	3.2	11
176	Mapping of Genomic Vulnerabilities in the Post-Translational Ubiquitination, SUMOylation and Neddylation Machinery in Breast Cancer. <i>Cancers</i> , 2021, 13, 833.	1.7	11
177	Transcriptomic analyses identify association between mitotic kinases, PDZ-binding kinase and BUB1, and clinical outcome in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 1-8.	1.1	10
178	Antitumoral effect of Ocoxin, a natural compound-containing nutritional supplement, in small cell lung cancer. <i>International Journal of Oncology</i> , 2018, 53, 113-123.	1.4	10
179	MEK5 promotes lung adenocarcinoma. <i>European Respiratory Journal</i> , 2019, 53, 1801327.	3.1	10
180	CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia. <i>Oncotarget</i> , 2017, 8, 29679-29698.	0.8	10

#	ARTICLE	IF	CITATIONS
181	Signalling-competent truncated forms of ErbB2 in breast cancer cells: differential regulation by protein kinase C and phosphatidylinositol 3-kinase. <i>Biochemical Journal</i> , 1999, 344, 339.	1.7	9
182	A dominant-negative N-terminal fragment of HER2 frequently expressed in breast cancers. <i>Oncogene</i> , 2013, 32, 1452-1459.	2.6	9
183	Epigenetic modulation of FOXM1-gene interacting network by BET inhibitors in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 725-732.	1.1	9
184	PDCD4 limits prooncogenic neuregulin-ErbB signaling. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 1799-1815.	2.4	8
185	Phospho-kinase profile of colorectal tumors guides in the selection of multi-kinase inhibitors. <i>Oncotarget</i> , 2015, 6, 31272-31283.	0.8	8
186	Anticancer activity, phytochemical screening and acute toxicity evaluation of an aqueous extract of <i>Aristolochia longa</i> L.. <i>International Journal of Pharmaceutical and Phytopharmacological Research</i> , 2017, 6, 20.	0.1	8
187	Genetic and Pharmacologic Evidence That mTOR Targeting Outweighs mTORC1 Inhibition as an Antimyeloma Strategy. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 504-516.	1.9	7
188	Modulation of cereblon levels by anti-myeloma agents. <i>Leukemia and Lymphoma</i> , 2016, 57, 167-176.	0.6	7
189	Regulation of the prometastatic neuregulin-MMP13 axis by SRC family kinases: therapeutic implications. <i>Molecular Oncology</i> , 2017, 11, 1788-1805.	2.1	7
190	Screening and Preliminary Biochemical and Biological Studies of [RuCl(<i>p</i> -cymene)(<i>N</i> , <i>N</i> -bis(diphenylphosphino)-isopropylamine)] ₄ in Breast Cancer Models. <i>ACS Omega</i> , 2019, 4, 13005-13014.	1.6	7
191	MZ1 co-operates with trastuzumab in HER2 positive breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 106.	3.5	7
192	Multisite phosphorylation of P-Rex1 by protein kinase C. <i>Oncotarget</i> , 2016, 7, 77937-77949.	0.8	7
193	Transcriptomic Mapping of Non-Small Cell Lung Cancer K-RAS p.G12C Mutated Tumors: Identification of Surfaceome Targets and Immunologic Correlates. <i>Frontiers in Immunology</i> , 2021, 12, 786069.	2.2	7
194	A modular approach to trim cellular targets in anticancer drug discovery. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 6641-6645.	1.0	6
195	The immunoglobulin-like domain of neuregulins potentiates ErbB3/HER3 activation and cellular proliferation. <i>Molecular Oncology</i> , 2018, 12, 1061-1076.	2.1	6
196	Integrin $\alpha 6$ Protein Expression and Prognosis in Solid Tumors: A Meta-Analysis. <i>Molecular Diagnosis and Therapy</i> , 2020, 24, 143-151.	1.6	6
197	Generation of Antibody-Drug Conjugate Resistant Models. <i>Cancers</i> , 2021, 13, 4631.	1.7	6
198	Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 313.	3.5	6

#	ARTICLE	IF	CITATIONS
199	Surfaceome analyses uncover CD98hc as an antibody drug-conjugate target in triple negative breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 106.	3.5	6
200	Biological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 295-307.	2.7	5
201	Checkpoint Kinase 1 Pharmacological Inhibition Synergizes with DNA-Damaging Agents and Overcomes Platinum Resistance in Basal-Like Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9034.	1.8	5
202	mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer. <i>Molecular Cancer Research</i> , 2022, 20, 1108-1121.	1.5	5
203	Overexpression of RasN17 Fails to Neutralize Endogenous Ras in MCF7 Breast Cancer Cells. <i>Journal of Biochemistry</i> , 2005, 137, 731-739.	0.9	4
204	Impact of Availability of Companion Diagnostics on the Clinical Development of Anticancer Drugs. <i>Molecular Diagnosis and Therapy</i> , 2017, 21, 337-343.	1.6	4
205	Central Role of Cell Cycle Regulation in the Antitumoral Action of Ocoxin. <i>Nutrients</i> , 2019, 11, 1068.	1.7	4
206	JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia. <i>Biomedicine and Pharmacotherapy</i> , 2021, 144, 112330.	2.5	4
207	Transautocrine Signaling by Membrane Neuregulins Requires Cell Surface Targeting, Which Is Controlled by Multiple Domains. <i>Journal of Biological Chemistry</i> , 2011, 286, 24350-24363.	1.6	3
208	Genomic Correlates of DNA Damage in Breast Cancer Subtypes. <i>Cancers</i> , 2021, 13, 2117.	1.7	3
209	Thyrotrophin-Releasing Hormone Raises Cytosolic Free Calcium Concentration in Human Adenomatous Somatotrophs and Corticotrophs; Comparison with in vivo Responsiveness to Thyrotrophin-Releasing Hormone in Patients with Acromegaly or Cushing's Disease. <i>Journal of Neuroendocrinology</i> , 1991, 3, 51-56.	1.2	2
210	Phosphoinositide Hydrolysis and Ensuing Calcium and Potassium Fluxes: Role in the Action of EGF and Other Growth Factors. <i>Cellular Physiology and Biochemistry</i> , 1992, 2, 196-212.	1.1	2
211	Achilles' heel of triple negative cancer. <i>Oncoscience</i> , 2014, 1, 115-116.	0.9	2
212	Bryonia 1/2 dioica aqueous extract induces apoptosis and G2/M cell cycle arrest in MDA-MB 231 breast cancer cells. <i>Molecular Medicine Reports</i> , 2019, 20, 73-80.	1.1	2
213	The Activation of Fas Receptor by APO010, a Recombinant Form of Fas Ligand, Induces In Vitro and In Vivo Antimyeloma Activity.. <i>Blood</i> , 2007, 110, 1515-1515.	0.6	2
214	Novel Synthetic Lethality Approaches for Drug Combinations and Early Drug Development. <i>Current Cancer Drug Targets</i> , 2016, 17, 48-52.	0.8	2
215	Achilles™ heel of triple negative cancer. <i>Oncoscience</i> , 2014, 1, 763-764.	0.9	2
216	Achilles' heel of triple negative cancer. <i>Oncoscience</i> , 2014, 1, 763-4.	0.9	2

#	ARTICLE	IF	CITATIONS
217	Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer. International Journal of Molecular Sciences, 2022, 23, 5476.	1.8	2
218	Voltage-Operated Calcium-Channel Subtypes in Human Neuroblastoma and Rat Pheochromocytoma Cells. Annals of the New York Academy of Sciences, 1989, 560, 249-250.	1.8	1
219	An update into the pathophysiological role of HER2 in cancer: therapeutic implications. Clinical and Translational Oncology, 2007, 9, 543-544.	1.2	1
220	Altered proTGF β ₁ /cleaved TGF β ₁ ratios offer new therapeutic strategies in renal carcinoma. Journal of Experimental and Clinical Cancer Research, 2021, 40, 256.	3.5	1
221	Ocoxin oral solution demonstrates antiviral properties in cellular models. Experimental and Therapeutic Medicine, 2021, 22, 1127.	0.8	0
222	Synthetic lethality interaction between aurora kinases and CHEK1 inhibitors in ovarian cancer.. Journal of Clinical Oncology, 2017, 35, e17089-e17089.	0.8	0